Elisha W. Finney
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Viatris Wins FDA Approval for RYZUMVI and Advances Pacira Deal. Viatris secured U.S. FDA approval for RYZUMVI, a treatment for presbyopia, which is relevant to its partnership with Opus Genetics. The company is also moving forward with a deal involving Pacira, a development analysts are watching closely. These moves add to the company's pipeline and strategic direction.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Morgan Stanley raises Mettler-Toledo price target to $1,575. Morgan Stanley maintained an Equal-Weight rating on Mettler-Toledo while raising its price target to $1,575. This action aligns with the current average analyst target of $1,529.46, which sits below the stock's 52-week high of $1,619.58. The company is also scheduled to host an investor meeting in the near term.
Transaction History
| ICUI | ▼ Sell | Open Market | 378 | $69K | 8/11/2026 | View on chart |
| ICUI | ▲ Buy | Option Exercise | 1,254 | $0 | 5/13/2026 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 23,660 | $0 | 3/6/2026 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 1,175 | $0 | 3/6/2026 | View on chart |
| ICUI | ▲ Buy | Option Exercise | 1,285 | $133K | 11/11/2025 | View on chart |
| ICUI | ▼ Sell | Open Market | 1,285 | $180K | 11/11/2025 | View on chart |
| MTD | ▲ Buy | Grant | 63 | $0 | 11/11/2025 | View on chart |
| MTD | ▲ Buy | Option Exercise | 474 | $282K | 11/10/2025 | View on chart |
| MTD | ▼ Sell | Open Market | 474 | $680K | 11/10/2025 | View on chart |
| ICUI | ▼ Sell | Open Market | 600 | $83K | 5/19/2025 | View on chart |
| ICUI | ▲ Buy | Option Exercise | 1,723 | $0 | 5/13/2025 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 773 | $0 | 3/4/2025 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 18,204 | $0 | 3/4/2025 | View on chart |
| MTD | ▲ Buy | Grant | 71 | $0 | 11/12/2024 | View on chart |
| MTD | ▼ Sell | Open Market | 76 | $100K | 11/11/2024 | View on chart |
| ICUI | ▼ Sell | Open Market | 300 | $31K | 5/16/2024 | View on chart |
| ICUI | ▲ Buy | Option Exercise | 948 | $0 | 5/15/2024 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 17,970 | $0 | 3/3/2024 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 885 | $0 | 3/3/2024 | View on chart |
| MTD | ▲ Buy | Option Exercise | 251 | $169K | 2/12/2024 | View on chart |
| MTD | ▼ Sell | Open Market | 251 | $296K | 2/12/2024 | View on chart |
| MTD | ▲ Buy | Grant | 49 | $0 | 11/9/2023 | View on chart |
| ICUI | ▼ Sell | Open Market | 194 | $37K | 6/7/2023 | View on chart |
| ICUI | ▲ Buy | Option Exercise | 485 | $0 | 5/17/2023 | View on chart |
| MTD | ▲ Buy | Option Exercise | 225 | $151K | 11/14/2022 | View on chart |
| MTD | ▼ Sell | Open Market | 20 | $30K | 11/14/2022 | View on chart |
| MTD | ▼ Sell | Open Market | 105 | $156K | 11/14/2022 | View on chart |
| MTD | ▼ Sell | Open Market | 100 | $148K | 11/14/2022 | View on chart |
| MTD | ▲ Buy | Grant | 41 | $0 | 11/3/2022 | View on chart |
| ICUI | ▼ Sell | Gift | 743 | $0 | 5/13/2022 | View on chart |
| ICUI | ▼ Sell | Open Market | 217 | $37K | 5/12/2022 | View on chart |
| ICUI | ▲ Buy | Option Exercise | 433 | $0 | 5/11/2022 | View on chart |
| MTD | ▲ Buy | Grant | 30 | $0 | 11/4/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
ICU Medical Highlighted in Zacks Industry Outlook
ICU Medical was featured in recent Zacks industry outlooks alongside Neogen and Trulieve, with analysts noting that certain medical product stocks are positioned to benefit from broader industry tailwinds. These mentions suggest continued analyst attention to the company's role in the medical device sector. The stock currently trades with a high trailing P/E of 135.9, while the average analyst target price stands at $193.38.
ICU Medical Highlighted in Zacks Industry Outlook. ICU Medical was featured in recent Zacks industry outlooks alongside Neogen and Trulieve, with analysts noting that certain medical product stocks are positioned to benefit from broader industry tailwinds. These mentions suggest continued analyst attention to the company's role in the medical device sector. The stock currently trades with a high trailing P/E of 135.9, while the average analyst target price stands at $193.38.